Navigation Links
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
Date:3/13/2008

of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease. Further, the results of earlier clinical trials may not be predictive of future results; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
2. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...MOUNTAIN VIEW, Calif., July 24 /PRNewswire-FirstCa... ) announced today that it has initiated,its secon...loxapine).,AZ-004 is an inhalation product candida...ation in patients with schizophrenia or bipolar di...ture and rapid pharmacokinetic,(PK) properties res...
(Date:7/24/2008)...WASHINGTON, July 24 /PRNewswire-USNewswire/ -- Hea...o not tell the whole story. The small scale,preli...line in Human,Reproduction, is based on recollecte...taining soyfoods. "This study is confounded by man... with a great deal of,caution," warned Dr. Tammy H...
(Date:7/24/2008)...Revolutionary thermometer designed to take body te...., July 24 /-- Kidz-Med, In...c. Pink Sheets: ASFX),United States distributor o...r, is pleased to announce the results of a clinica...of the University of Milan, in,Milan, Italy, which...
(Date:7/24/2008)...SOPHIA ANTIPOLIS, France, July 24 /PRNewswire-Firs...nnounced the top-line results from the 52-week,ope...ing the completion of,the 301 phase 3 study for na...ty findings and efficacy was maintained for the on...atients, global assessment scale. In,addition, the...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Diagnostic Imaging New Stock Symbol OTCBB 3A DIIG 3077 1Diagnostic Imaging New Stock Symbol OTCBB 3A DIIG 3077 2Diabetes Growth Disorders Drive Sales of Pediatric Hormone Drugs 11166 1Diabetes Growth Disorders Drive Sales of Pediatric Hormone Drugs 11166 2New study suggests link between environmental toxins and early onset puberty in girls 11163 1New study suggests link between environmental toxins and early onset puberty in girls 11163 2Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 3074 1Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 3074 2Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 3074 3Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 3074 4
...ropean Hematology,Association (EHA) -, VIENNA, Aus...nomedics, Inc. , a biopharmaceutical company focus...ncer and other serious,diseases, today announced t...Vienna, Austria, showed positive responses in pati...h a new,radioimmunotherapy (RAIT) using epratuzuma...
...007 - Geron,Corporation (Nasdaq:GERN) today announ...g that GRNOPC1, the company,s human,embryonic stem...f,spinal cord injury, evades a direct attack by th...st Ross Okamura at the Federation of,Clinical Immu...s,could mean that patients treated with GRNOPC1 wo...
Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3
(Date:7/25/2008)...s of Marketing Exclusivity Begins -, CORONA, Cali...aceuticals, Inc. (NYSE: WPI ), a leading specialt... subsidiary has commenced commercial,shipment of i... in the 40mg,strength from its Davie, Florida manu..., Watson has 180 days of marketing exclusivity for...
(Date:7/25/2008)...ion Executive, Robert J. Reilly, Joins Aethon Team...,( http://www.aethon.com ), the leading developer ...tics, today announced that Robert J. Reilly has,jo... Financial Officer., Reilly, who was most recentl...orporation,s Specialty Pharmacy Division, brings m...
(Date:7/25/2008)...ewswire/ -- The Elekta Family of Companies will,sh...ions at the 2008,American Association of Physicist... how the joint forces of Elekta, IMPAC and CMS are...g and delivery solutions that,streamline the treat...ients, as well as enhance clinician efficiency., ...
(Date:7/25/2008)...y 25 /PRNewswire/ -- AutoGenomics, Inc. today,anno...n Form S-1 with the,Securities and Exchange Commis...ing of shares of its common stock. The number of s...are expected to be offered by,AutoGenomics, Inc., ... been,determined., J.P. Morgan Securities Inc. is...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...ng 20 paintings by renowned masters like M.F. Husa...ment a similar theme to be etched out at Sunday's ...Week. "There are different kinds of desire in a h... fulfilled, some only dream about it. But it's som...
...n people as young as 16 whereas the phenomenon onc... says. "Nobody can escape stress in modern day li...cts like a male hormone and causes the thinning of... Shah said. "Initially, we used to see this begin...
...Saturday in Burhanpur district of Madhya Pradesh i...Maharashtra testing positive for the deadly bird f...ation will also be paid to 323 affected poultry ow...cted," said Rajesh Rajora, commissioner of the sta...
...University are pumping for a controversial theory,...e forced// into "dark states" where they can be ea... idea appears to contravene some of the most accep...y, not long ago dismissed as impossible by much of...
Other Medicine News:Health News:India Fashion Week Reveals - 'The Story Of Desire' 2Health News:Stress Can Cause Hair loss at 16 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 3
2-ply material consisting of polyethylene film inner layer and non-woven outer layers.
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and
The cardiac blanket is pre-positioned at the waist during prep, unrolled upon closure of the saphenous vein graft incision, and inflated post-bypass.
The full access underbody blanket is positioned on the procedure table before the patient arrives to the room.
Medicine Products: